Skip to main content
. 2020 Jun 27;36(8):1474–1483. doi: 10.1093/ndt/gfaa117

FIGURE 2.

FIGURE 2

Overview of the clinical responses, renal responses and concomitant immunosuppression upon RTX + BLM treatment. (A) Achievement of LLDAS over time. (B) Achievement of a renal response in patients included with active LN (n = 12). CRR was achieved when proteinuria ≤0.7 g/day, normal serum albumin, stable kidney function and normal urinary sediment; partial response: >0.7–2.9g/24 h with a decrease in proteinuria of ≥50% from baseline, serum albumin >30 g/L and stable kidney function. When patients did not meet any of these criteria, they were considered to have persistent active LN. (C) Overview of concomitant treatment with BLM, MMF and prednisolone throughout the study’s follow-up. Patient numbers mentioned on the y-axis correspond between the three figures. SACQ, serologically active (positive antibody and or low complement) clinically quiescent.